The University of Chicago, Chicago, IL
Peter H. O'Donnell , Arjun Vasant Balar , Daniel E. Castellano , Ronald De Wit , David J. Vaughn , Thomas Powles , Jacqueline Vuky , Jae-Lyun Lee , Yves Fradet , Joaquim Bellmunt , Lawrence Fong , Daniel P. Petrylak , Winald R. Gerritsen , David I. Quinn , Stephane Culine , Dean F. Bajorin , Jin Zhi Xu , Kentaro Imai , Blanca Homet Moreno , Petros Grivas
Background: Pembro showed antitumor activity in 1L and 2L for pts with UC in the single-arm, phase 2 KEYNOTE-052 study (NCT02335424) and the randomized phase 3 KEYNOTE-045 (NCT02256436) study, respectively. This post hoc exploratory analysis evaluated whether primary tumor location affected efficacy and safety of pembro (KEYNOTE-052; KEYNOTE-045) and chemotherapy (chemo; KEYNOTE-045). Methods: KEYNOTE-052 enrolled cisplatin-ineligible pts with advanced/metastatic UC who had not previously received systemic therapy; they received pembro (200 mg IV Q3W). KEYNOTE-045 enrolled pts with advanced/metastatic UC who had received platinum-containing chemo; pts were randomly assigned 1:1 to receive pembro (200 mg IV Q3W) or investigator’s choice of chemo (paclitaxel, docetaxel, or vinflunine). Both studies required pts to have measurable disease per RECIST v1.1. Upper tract (UT) UC included primary tumors in the renal pelvis or ureter; lower tract (LT) UC included primary tumors in the bladder or urethra. Pts with UT and LT disease (UT/LT) were classified as LT. Pts receiving pembro were treated until disease progression, unacceptable toxicity, or withdrawal of consent, for up to 2y. End points were PFS, ORR, and DOR per RECIST v1.1 by central radiology assessment and OS. Results: A total of 369 pembro-treated pts (68 UT; 301 LT [79 UT/LT]) from KEYNOTE-052 plus 270 pembro-treated pts (93 UT; 177 LT [33 UT/LT]) and 272 chemo-treated pts (94 UT; 178 LT) from KEYNOTE-045 were evaluated. Median follow-up from randomization to data cutoff (09/26/20 and 10/1/20, respectively) was ≥56 mo. Both studies enrolled a similar percentage of pts with PD-L1–positive tumors (25%-30%). PFS, ORR, DOR, and OS for pembro were consistent regardless of tumor location, although ORR for KEYNOTE-045 was lower for the UT group (Table). In the chemo arm of KEYNOTE-045, similar efficacy was observed regardless of tumor location or regimen. Grade 3-5 TRAEs occurred at similar rates in KEYNOTE-052 (19.1% UT; 21.6% LT) and KEYNOTE-045 (17.2% UT; 16.8% LT). Conclusions: In this exploratory analysis, pembro showed similar clinical activity and manageable safety regardless of primary UC tumor location. Clinical trial information: NCT02256436 and NCT02335424.
KEYNOTE-052 Upper (n = 68) | KEYNOTE-052 Lower (n = 301) | KEYNOTE-045 Upper (n = 93) | KEYNOTE-045 Lower (n = 177) | |
---|---|---|---|---|
ORR, % (95% CI) | 26.5 (16.5-38.6) | 29.6 (24.5-35.1) | 14.0 (7.7-22.7) | 26.0 (19.7-33.1) |
DOR, median (range), moa | 35.8 (2.8 to 57.3+) | 33.2 (1.4+ to 60.7+) | 24.6 (6.2+ to 51.1+) | 29.7 (1.6+ to 60.5+) |
OS, median (95% CI), mo | 10.8 (7.6-17.0) | 11.5 (9.7-13.1) | 9.7 (7.7-14.0) | 10.1 (7.3-12.5) |
PFS, median (95% CI), mo | 2.8 (1.9-3.5) | 2.5 (2.1-3.4) | 2.1 (2.0-2.2) | 2.1 (2.0-3.4) |
a+ indicates no progressive disease by the time of last disease assessment.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Manish A. Shah
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Zev A. Wainberg
2023 ASCO Annual Meeting
First Author: Luciana Vinti
2023 ASCO Annual Meeting
First Author: Patrizia Giannatempo